Details

NameSymbolSector
BAL PHARMA LTD.BALPHARMAPharmaceuticals
Open
87
High
90.9
Low
87
Close
87.78
Volume
52797
Exchange
nse
Time
15-Jun-2026

Outlook

Score:  

4

Rating:  

FAIR

Candlestick Pattern

Candle pattern of Bal Pharma is  
High Wave
Estimated Stoploss of Bal Pharma is ₹  
87
Bal Pharma has a  
Bullishℹ
 pattern. 
Formation of  
High Wave
 candle pattern indicates the trend direction of Bal Pharma is  
Unpredictableℹ
. 

Trend

Bal Pharma is in  
Sideways trendℹ
. 
Price of Bal Pharma is  
Upℹ
 by  

7.49

%. 
Target
Buy @ 

61.79

Sell @ 

93.47

Current @ 

87.78

Volume

The trades of Bal Pharma have been in  
Immenseℹ
 volume. 
The volume trades for Bal Pharma are  
Bullishℹ
 with  
Strong Buyersℹ
The trade volume of Bal Pharma is  

Up

 by  

84.67

% 

Valuation

The current market price of Bal Pharma is  
Undervaluedℹ

Financials

Balance
With total liablities and shareholder equity worth ₹ 335cr and total assets worth ₹ 335cr, the balance sheet of Bal Pharma is:  
Balancedℹ
. 
Cashflow
Bal Pharma has  
Poorℹ
 cash flow because there is  

Shortage

 of  

₹ 2cr

. It is  
Downℹ
 by  

200

%. 

(*Mar 2025)

48.78% i.e. ₹ 20cr earned in operatingℹ
34.15% i.e. ₹ 14cr spent in investingℹ
17.07% i.e. ₹ 7cr spent in financingℹ
0% in otherℹ
Bal Pharma has  
Sufficientℹ
 cash flow because there is  

Surplus

 of  

₹ 2cr

. It is  
Upℹ
 by  

0

%. 

(*Mar 2024)

53.66% i.e. ₹ 22cr earned in operatingℹ
43.9% i.e. ₹ 18cr spent in investingℹ
2.44% i.e. ₹ 1cr spent in financingℹ
0% in otherℹ
Income
The income of Bal Pharma is  

₹ 75cr

 and  

Loss

 is :  

₹ 0cr

(*Sep 2025)

Bal Pharma Losses increased by:  

0

% and Income is Up by:  

13.64

% 

(*Sep 2025)

The income of Bal Pharma is  

₹ 66cr

 and  

Loss

 is :  

₹ 0cr

(*Jun 2025)

Bal Pharma Losses increased by:  

100

% and Income is Down by:  

19.51

% 

(*Jun 2025)

The income of Bal Pharma is  

₹ 82cr

 and  

Profit

 is :  

₹ 5cr

(*Mar 2025)

Bal Pharma Profit is up by:  

500

% and Income is Up by:  

12.33

% 

(*Mar 2025)

By using this site you agree to the use of cookies to deliver a better site experience.